ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,114.63
-0.01%
Dow Jones
44,546.08
-0.37%
US Dollar vs MXN
20.38155
0.37%
Brent Oil
74.675
0.59%
Bitcoin
96,237.38
0.11%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Zymeworks Inc (ZYME) Cotización

Zymeworks Inc

Zymeworks Inc (ZYME)

NASDAQ
15.01
0.39
(2.67%)
Cerrado 17 Febrero 3:00PM
Delayed by 15 minutes
15.55
0.54
(3.60%)
Fuera de horario: 6:59PM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
15.01
Postura de Compra
14.98
Postura de Venta
17.00
Volume Operado de la Acción
242,322
14.56 Rango del Día 15.155
7.97 Rango de 52 semanas 17.70
Capitalización de Mercado [m]
1.034B
Precio Anterior
14.62
Precio de Apertura
14.73
Hora
50
@
14.99
Última hora de negociación
Volumen financiero
US$ 3,617,004
Precio Promedio Ponderado
14.9264
Volumen promedio (3 m)
448,228
Acciones en circulación
68,877,526
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-8.72
Beneficio por acción (BPA)
-1.72
turnover
76.01M
Beneficio neto
-118.67M

Acerca de Zymeworks Inc

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiat... Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.zymeworks.com
Sede
Wilmington, Delaware, USA
Fundado
-
Zymeworks Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZYME. The last closing price for Zymeworks was US$14.62. Over the last year, Zymeworks shares have traded in a share price range of US$ 7.97 to US$ 17.70.

Zymeworks currently has 68,877,526 shares in issue. The market capitalisation of Zymeworks is US$1.01 billion. Zymeworks has a price to earnings ratio (PE ratio) of -8.72.

ZYME Últimas noticias

Más noticias

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
10 Enero 2025
ZYME (2.67%)

Form 8-K - Current report
Edgar (US Regulatory)
08 Enero 2025
ZYME (2.67%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
06 Enero 2025
ZYME (2.67%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
06 Enero 2025
ZYME (2.67%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
12 Diciembre 2024
ZYME (2.67%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
12 Diciembre 2024
ZYME (2.67%)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.221.4874915483414.7915.5512.821540598214.1139714CS
40.96.3784549964614.1115.5512.821533362314.38999533CS
121.279.2430858806413.7417.0712.4344822814.07563353CS
264.7346.011673151810.2817.79.99554829713.29932011CS
523.6131.666666666711.417.77.9759045711.40647086CS
1568.63135.266457686.3817.76.0156089859.80517701CS
2608.63135.266457686.3817.76.0156089859.80517701CS

ZYME - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Zymeworks?
El precio actual de las acciones de Zymeworks es US$ 15.01
¿Cuántas acciones de Zymeworks están en circulación?
Zymeworks tiene 68,877,526 acciones en circulación
¿Cuál es la capitalización de mercado de Zymeworks?
La capitalización de mercado de Zymeworks es USD 1.01B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Zymeworks?
Zymeworks ha negociado en un rango de US$ 7.97 a US$ 17.70 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Zymeworks?
El ratio precio/beneficio de Zymeworks es -8.72
¿Cuál es el ratio de efectivo a ventas de Zymeworks?
El ratio de efectivo a ventas de Zymeworks es 13.61
¿Cuál es la moneda de reporte de Zymeworks?
Zymeworks presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Zymeworks?
El último ingresos anual de Zymeworks es USD 76.01M
¿Cuál es el último beneficio anual de Zymeworks?
El último beneficio anual de Zymeworks es USD -118.67M
¿Cuál es la dirección registrada de Zymeworks?
La dirección registrada de Zymeworks es CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Zymeworks?
La dirección del sitio web de Zymeworks es www.zymeworks.com
¿En qué sector industrial opera Zymeworks?
Zymeworks opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
JTAIJet AI Inc
US$ 6.02
(133.33%)
104.48M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
254.39M
WRDWeRide Inc
US$ 31.4877
(83.39%)
21.07M
INLFINLIF Limited
US$ 16.27
(80.58%)
7.68M
MBRXMoleculin Biotech Inc
US$ 2.1201
(66.94%)
136.66M
BLACBellevue Life Sciences Acquisition Corporation
US$ 3.08
(-56.31%)
425.19k
BLACUBellevue Life Sciences Acquisition Corporation
US$ 3.36
(-52.68%)
5.21k
CSAICloudastructure Inc
US$ 19.0001
(-49.58%)
1.01M
NEXNNexxen International Ltd
US$ 10.30
(-49.16%)
160.99k
BSLKBolt Projects Holdings Inc
US$ 0.6626
(-46.13%)
13.07M
CNSPCNS Pharmaceuticals Inc
US$ 0.1415
(31.26%)
480.49M
MGOLMGO Global Inc
US$ 0.7176
(-15.08%)
411.17M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
248.48M
INTCIntel Corporation
US$ 23.60
(-2.20%)
225.04M
NVDANVIDIA Corporation
US$ 138.85
(2.63%)
189.56M

Discusión

Ver feed completo
cecilburrow cecilburrow 14 minutos hace
Are you kidding? From the latest 8k:

> AiAdvertising, Inc. (the “Company”) has received termination and non-renewal notices from two of its three largest customers. These customers account for approximately 40% of the Company’s annual revenues. As a result of these termination notices
AIAD
Golden Cross Golden Cross 19 minutos hace
Looking good here........
DTII
robinandthe7hoods robinandthe7hoods 27 minutos hace
'Integrates with existing systems...'
'Interoperable...'

"VERSES Announces the First Wayfinder-Based AI Routing Agent" https://www.globenewswire.com/news-release/2023/06/26/2694144/0/en/VERSES-Announces-the-First-Wayfinder-Based-AI-Routing-Agent-for-Multi-System-Spatial-Computi
VRSSF
Seminole Red Seminole Red 35 minutos hace
well, thats a tough course,
The ELTP King The ELTP King 38 minutos hace
There's still a chance we receive a press release about the new facility.

As evidenced below, the press release was NOT issued upon the FDA approval of the facility, but rather the FIRST SHIPMENT from the new facility.

Elite's new facility wasn't approved until February
ELTP
fuagf fuagf 48 minutos hace
Was surprised on seeing i was the only one with Scheffler captain, and after
Day 2 thinking that was the way to the top. One bad day, for some reason.

Thanks.
manibiotech manibiotech 52 minutos hace
If my statement can create a bottom , it would happened years ago 


NWBO
Seminole Red Seminole Red 1 hora hace
YUK
Seminole Red Seminole Red 1 hora hace
nice win, Big points
robinandthe7hoods robinandthe7hoods 1 hora hace
Even way back in the Wayfinder days of 2023,the Verses technology,now called Genius was built to fit on top of existing systems,both software and hardware,integrate and enhance the system already in place to maximize the capabilities for each company.
Genius is not made to replace,but to
VRSSF
fuagf fuagf 1 hora hace
Remind us how much Trump cares for the Bill of Rights, or any other part of the Constitution. Or the other jerk...

https://www.usnews.com/object/image/00000195-0583-d285-a7bf-7f9fb4c30000/20250212edohc-a.jpg?update-time=1739554653232&size=responsiveGallery
eagle8 eagle8 2 horas hace
autologous assassin 🇺🇸 🇺🇦 🇮🇱
@flaskworks
Roswell Park Cancer Institute, a world-renowned leader in immunotherapy research, wouldn’t have signed over their 27-year dendritic cell IP portfolio to $NWBO unless they had full confidence in the
NWBO
fuagf fuagf 2 horas hace
Holy catfish. Thanks. ;-)
igotthemojo igotthemojo 2 horas hace
they built facilities and never said where, except to say it was in Vietnam...they could have built it in Quang Nam on the property they are already leasing...but why would they build a facilty there if they already had a facility there?...

LAREC and the VSA may have provided a locati
KBLB
fuagf fuagf 2 horas hace
Teachable. Ask which is heavier, dry or humid air .. stop! .. don't read any more until you answer

















https://www.washingtonpost.com/news/capital-weather-g
fuagf fuagf 2 horas hace
Maybe he'll have visited by the time he gets back.
Dragonman1 Dragonman1 2 horas hace
Just Waiting for the Quarterly Report and if it's what I expect it should be epic, who doesn't like beer and also where the super bashers are then you should know that is a good sign, they want it to fail but that won't happen,
IMHO this Co is gonna take off sooner or later, remember bashers
KEGS
TightCoil TightCoil 2 horas hace
Ask: Does HawkEye Buffett know something
about Fannie and Freddie that we don't know.
And is he preparing to do something shocking?
FNMA
oldstocks oldstocks 2 horas hace
Proof OneMind Technologies is part of the Spain 2025 push Digital Transformation as in part of the Kit Consulting

This is huge for OneMind Technologies and it is only starting to sink into our minds here, after OneMindNG post on LinkedIn 2 weeks ago!

I knew i stumbled
AFFU
demonsmith demonsmith 2 horas hace
One day closer to trading
TWOH
Budman33 Budman33 3 horas hace
Not to late to buy. Anyone have a shiny crystal 🔮 for Fridays close. IMO higher than where we are. Stock acting beautiful.
VDRM
fuagf fuagf 3 horas hace
LOL Haven't seen any sign he would appreciate anything.

Anyway, only notice, B4 out for two, usher for three. Weeks this time.

Life will be easier.
lodas lodas 3 horas hace
I am becoming more and more skeptical as we head into uncharted waters with this new administration....Perception is everything on wall street, so here is a couple of game changers to think about.... (1) Warren Buffet has been quietly liquidating stocks in his portfolio.... (2) Deep Seek has thrown
NVDA
Alexulf Alexulf 3 horas hace
Oh dear :-) who and what are you? LOL :-) you are stuck in a self-destructive behavior.
Chill, just chill. This rambling on of yours eats you up, not healthy at all, seriously!
AITX

Su Consulta Reciente

NASDAQ
ZYME
Zymeworks
LSE
0P3K
Dedicare Ab (publ)
EXMO
STQUSD
Storiqa
USOTC
PIKQF
Pt Indah Kiat Pulp (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios